The whole of the big three are still wildly outspent by the likes of Apple, Microsoft and Amazon (but each of those three post revenues that are multiples of the life-sciences big three). Take a look here, at relative upstart -- Amgen (compared to over a two-thirds of a century at Pfizer, and well-over a century -- at Merck):
. . .Biosimilars, no specific bill; Prescription drug value issues, no specific bill; S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1245 Affordable and Safe Prescription Drug Importation Act; 340B Protecting Access for the Underserved and Safety-Net Entities (340B PAUSE Act); FDA issues, no specific bill; S.3158 Labor, Health and Human Services Appropriations Act (Senate Report 115-289); Issues related to International Pricing Index (IPI), no specific bill; S. 551 Recovering Excessive Funds for Unused and Needless Drugs Act; S. 657 Drug Price Transparency Act; S. 658 Accelerated Drug Approval for Prescription Therapies Act; S. 660 Efficiency and Transparency in Petitions Act; S. 1895, Lower Health Care Costs Act (S. 1895), a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs; S. 1391, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act (S. 1391); H.R. 1499, Protecting Consumer Access Generic Drugs Act; H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act; S. 1169, Ensuring Timely Access to Generics Act; S. 1617, Second Look at Drug Patents Act; H.R. 1520, Purple Book Continuity Act; S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act; S. 977, Transparent Drug Pricing Act; S. 102, Prescription Drug Price Relief Act; S. 637, Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act; S. 659, Biologic Patent Transparency Act; H.R. 1503, Orange Book Transparency Act; H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act; S. 1664, Prescription Drug Price Reporting Act. . . .
Medicare Part B coverage and reimbursement issues; Coding and reimbursement for biologics/biosimilars; HR 6505 - Medicare Negotiation and Competitive Licensing Act (Doggett compulsory licensing bill); Issues related to Part D coverage gap, no specific bill; S. 1676 Chronic Kidney Disease Improvement in Research and Treatment Act; Transitional drug add-on payment (TDAPA), dialysis bundled payment system issues; H.R. 6142 Reducing Drug Waste Act of 2018; Issues related to the 340b program, no specific bill; Drug Price Transparency Bills: HR 2296/S 1391 FAIR Drug Pricing Act; HR 2113 Prescription Drug STAR Act; HR 2069 SPIKE Act; S 1416 Affordable Prescriptions for Patients Act; Issues related to Direct to Consumer Advertisement; S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act; S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act; S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act; H.R. 2087, Drug Price Transparency Act. . . .
International Tax issues including:; H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for the fiscal year; Puerto Rico Tax Incentives. . . .
S. 974 CREATES Act of 2017; S. 124 Preserve Access to Affordable Generics Act; Issues related to drug patents and exclusivities (no bill); H.R. 1520, Purple Book Continuity Act of 2019; H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019; S. 1224, The Stop STALLING Act; S. 1416, The Affordable Prescriptions for Patients Act, on product hopping and patent thicketing. . . .
United States-Mexico-Canada Trade Agreement, no specific bill. . . .
That's it. I may or may not post all the telecom, internet and cyber-security matters that Amazon has lobbied on, in addition to its portfolio on health care and employee welfare plans -- as well as union busting measures. We shall see. Grin.
नमस्ते
No comments:
Post a Comment